62179-79-7

Basic information

• Product Name: Ethanone, 2-bromo-1-[4-(pentyloxy)phenyl]-
• CAS NO: 62179-79-7
• Molecular Formula: C13H17BrO2
• Molecular Weight: 285.181
• Mol File: 62179-79-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Ethanone, 2-bromo-1-[4-(pentyloxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-[4-(pentyloxy)phenyl]-(62179-79-7)
• EPA Substance Registry System: Ethanone, 2-bromo-1-[4-(pentyloxy)phenyl]-(62179-79-7)

Safety Data

• Hazardous Substances Data: 62179-79-7(Hazardous Substances Data)

Upstream product

• 110-53-2 1-Bromopentane 
• 5467-56-1 4-pentyloxyacetophenone 
• 38932-80-8 tetra-N-butylammonium tribromide 
• 99-93-4 4-Hydroxyacetophenone 
• 186581-53-3 diazomethane 
• 36823-84-4 4-pentyloxybenzoyl chloride 

Downstream Products

• 130623-08-4 2-(4,5-Dihydro-1H-imidazol-2-ylsulfanyl)-1-(4-pentyloxy-phenyl)-ethanone; hydrobromide 
• 89238-79-9 2-Diethylamino-1-(4-pentyloxy-phenyl)-ethanone 
• 88675-35-8 2-Azepan-1-yl-1-(4-pentyloxy-phenyl)-ethanone 

Relevant articles and documents

Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold

Tuberculosis (TB) remains a significant global health problem for which new therapeutic options are sorely needed. The ability of the causative agent, Mycobacterium tuberculosis, to reside within host macrophages and form biofilm-like communities contributes to the persistent and drug-tolerant nature of the disease. Compounds that can prevent or reverse the biofilm-like phenotype have the potential to serve alongside TB antibiotics to overcome this tolerance, and decrease treatment duration. Using Mycobacterium smegmatis as a surrogate organism, we report the identification of two new 2-aminoimidazole compounds that inhibit and disperse mycobacterial biofilms, work synergistically with isoniazid and rifampicin to eradicate preformed M. smegmatis biofilms in vitro, are nontoxic toward Galleria mellonella, and exhibit stability in mouse plasma.

SUBSTITUTE 4-ARYLBUTYRIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The compounds of the invention have generalized formula (I) wherein R represents C6-C12 alkyl; C5-C12 alkoxy; C5-C12 alkylthio; a polyether of formula RO(C2H4O)a- in which a is 1 or 2 and R is C1-C5 alkyl, phenyl, or benzyl; and substituted alkynyl of formula R(CH2)b-CC-; in which b is 1-10 and R is H-, HO-, or RO- in which R is C1-C3 alkyl, phenyl, or benzyl. The alkyl, phenyl, and benzyl portions of R may bear at least one pharmaceutically-acceptable substituent. The subscript n is 2-4. R represents phenyl; imidoyl of 4-12 carbon atoms; (3H)-benzo-1,2,3-triazin-4-on-3-yl; N-saccharinyl; (2H)-phthalazin-1-on-2-yl; 2-benzoxazolin-2-on-3-yl; 5,5-dimethyloxazolidine-2,4-dion-3-yl; and thiazolidine-2,4-dion-3-yl; with the phenyl and benzo portions of R permissibly bearing at least one pharmaceutically-acceptable substituent. Pharmaceutically acceptable salts of these materials are also included.